Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on X:
“Such a delight to co‑chair the tumor‑agnostic and basket trials session with the amazing Dr. Keith Flaherty.
Lively discussion on pan‑cancer drug development, MCED testing, and Australia’s leap into tumor‑agnostic immunotherapy reimbursement.
Read our ipi + Nivo and pembro for all cancers.”
Title: Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia’s Landmark Tumor-Agnostic Immunotherapy Reimbursement
Authors: Vivek Subbiah, Razelle Kurzrock.
Read The Full Article.
You can also read: CheckMate 214 Updates: Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced RCC
